OXFORD, England & VIENNA, Austria--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback